UniQure Operating Margin 2013-2022 | QURE
Current and historical operating margin for UniQure (QURE) over the last 10 years. The current operating profit margin for UniQure as of December 31, 2022 is -119.07%.
| UniQure Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2022-09-30 |
$0.06B |
$-0.17B |
-275.41% |
| 2022-06-30 |
$0.06B |
$-0.15B |
-246.77% |
| 2022-03-31 |
$0.53B |
$0.30B |
57.22% |
| 2021-12-31 |
$0.52B |
$0.31B |
59.35% |
| 2021-09-30 |
$0.50B |
$0.30B |
60.20% |
| 2021-06-30 |
$0.50B |
$0.30B |
60.40% |
| 2021-03-31 |
$0.04B |
$-0.13B |
-352.63% |
| 2020-12-31 |
$0.04B |
$-0.12B |
-326.32% |
| 2020-09-30 |
$0.01B |
$-0.15B |
-2128.57% |
| 2020-06-30 |
$0.01B |
$-0.14B |
-2266.67% |
| 2020-03-31 |
$0.01B |
$-0.13B |
-2116.67% |
| 2019-12-31 |
$0.01B |
$-0.12B |
-1728.57% |
| 2019-09-30 |
$0.01B |
$-0.11B |
-1866.67% |
| 2019-06-30 |
$0.01B |
$-0.10B |
-1300.00% |
| 2019-03-31 |
$0.01B |
$-0.10B |
-1066.67% |
| 2018-12-31 |
$0.01B |
$-0.09B |
-800.00% |
| 2018-09-30 |
$0.01B |
$-0.09B |
-725.00% |
| 2018-06-30 |
$0.01B |
$-0.07B |
-663.64% |
| 2018-03-31 |
$0.01B |
$-0.07B |
-553.85% |
| 2017-12-31 |
$0.01B |
$-0.07B |
-553.85% |
| 2017-09-30 |
$0.02B |
$-0.07B |
-342.11% |
| 2017-06-30 |
$0.02B |
$-0.07B |
-291.67% |
| 2017-03-31 |
$0.02B |
$-0.07B |
-313.04% |
| 2016-12-31 |
$0.02B |
$-0.07B |
-295.83% |
| 2016-09-30 |
$0.02B |
$-0.06B |
-315.79% |
| 2016-06-30 |
$0.02B |
$-0.08B |
-475.00% |
| 2016-03-31 |
$0.01B |
$-0.08B |
-535.71% |
| 2015-12-31 |
$0.01B |
$-0.07B |
-645.45% |
| 2015-09-30 |
$0.01B |
$-0.08B |
-922.22% |
| 2015-06-30 |
$0.01B |
$-0.07B |
-1150.00% |
| 2015-03-31 |
$0.01B |
$-0.06B |
-1220.00% |
| 2014-12-31 |
$0.01B |
$-0.06B |
-933.33% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.946B |
$0.106B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
